Business Context and Reporting Period
This Form 8-K Current Report from CG Oncology, Inc. covers events occurring on November 22, 2025. The filing addresses significant changes to the Company's Board of Directors, specifically the appointment of a new director and the resignation of an existing director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Appointment of Christina Rossi: Effective November 24, 2025, Ms. Rossi was appointed as a Class II director. Her term expires at the 2026 annual meeting.
- Resignation of Simone Song: Effective immediately on November 22, 2025, Ms. Song resigned from the Board and all committees (Audit Committee member and Compensation Committee chair). The resignation was not due to any disagreement with the Company.
Compensation and Governance Details
As part of her appointment, Christina Rossi will receive:
- Cash Compensation: $45,000 per calendar year, payable in quarterly installments.
- Equity Award: An initial grant of 20,889 options to purchase common stock.
- Vesting Schedule: Options vest in substantially equal monthly installments over three years, contingent on continued service.
The Company has executed a standard indemnification agreement with Ms. Rossi. No other arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K were identified.
Investor Verification Checklist
- Verify the effective date of Christina Rossi's board service (November 24, 2025).
- Confirm the total number of options granted (20,889) and the three-year vesting schedule.
- Review the Company's updated Board composition following Simone Song's immediate resignation.
- Check for any subsequent filings regarding the appointment of a new chair for the Compensation Committee, given Ms. Song's prior role.